A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in
Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with
Anti-PD-1 or Anti-PD-L1 Antibodies